Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

APRE

Aprea Therapeutics Inc

Last Close
May 15 • 04:00PM ET
5.80
Dollar change
-0.09
Percentage change
-1.53 		%
Held by: VTI VXF DFAT DFSU DFAC
Index- P/E- EPS (ttm)-3.32 Insider Own11.91% Shs Outstand5.43M Perf Week12.95%
Market Cap31.49M Forward P/E- EPS next Y-1.41 Insider Trans2.66% Shs Float4.78M Perf Month-0.85%
Income-12.72M PEG- EPS next Q-0.60 Inst Own20.79% Short Float1.90% Perf Quarter-2.85%
Sales0.96M P/S32.81 EPS this Y33.00% Inst Trans-45.51% Short Ratio2.95 Perf Half Y43.21%
Book/sh5.33 P/B1.09 EPS next Y46.60% ROA-39.00% Short Interest0.09M Perf Year48.53%
Cash/sh5.96 P/C0.97 EPS next 5Y- ROE-43.83% 52W Range2.78 - 8.85 Perf YTD23.40%
Dividend Est.- P/FCF- EPS past 5Y23.41% ROI-42.06% 52W High-34.44% Beta1.11
Dividend TTM- Quick Ratio11.15 Sales past 5Y0.00% Gross Margin- 52W Low108.63% ATR (14)0.36
Dividend Ex-Date- Current Ratio11.15 EPS Y/Y TTM96.95% Oper. Margin-1452.49% RSI (14)54.53 Volatility7.86% 5.68%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin-1319.46% Recom1.00 Target Price15.67
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q50.17% Payout- Rel Volume0.37 Prev Close5.89
Sales Surprise- EPS Surprise11.84% Sales Q/Q- EarningsMay 14 BMO Avg Volume30.71K Price5.80
SMA208.14% SMA50-3.08% SMA20017.63% Trades Volume11,440 Change-1.53%
Date Action Analyst Rating Change Price Target Change
Dec-28-20Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20Initiated Berenberg Buy $37
Sep-29-20Resumed JP Morgan Neutral $25
Jun-22-20Initiated H.C. Wainwright Neutral $30
Apr-21-20Initiated Robert W. Baird Outperform $45
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
May-14-24 01:53PM
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
(InvestorPlace) +5.37%
08:30AM
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
(GlobeNewswire)
May-13-24 04:01PM
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
May-02-24 09:15AM
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-10-24 12:00PM
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
(GlobeNewswire)
01:53PM Loading…
Mar-26-24 01:53PM
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
07:45AM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Mar-11-24 08:30AM
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
(GlobeNewswire) -5.05%
08:29AM
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
(GlobeNewswire)
Mar-05-24 04:45PM
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
(GlobeNewswire)
Feb-06-24 08:01AM
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
(GlobeNewswire) +11.97%
Jan-30-24 08:00AM
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
(GlobeNewswire)
Jan-04-24 04:05PM
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
(GlobeNewswire)
Nov-09-23 04:05PM
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Oct-24-23 08:00AM
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
(GlobeNewswire)
08:30AM Loading…
Oct-16-23 08:30AM
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
(GlobeNewswire)
Sep-19-23 08:00AM
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Sep-11-23 08:00AM
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
(GlobeNewswire)
Sep-06-23 04:05PM
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-24-23 07:30AM
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
(GlobeNewswire)
Aug-10-23 07:30AM
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Jun-14-23 08:00AM
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
(GlobeNewswire)
May-30-23 08:30AM
Aprea Therapeutics to Present at BIO International Convention
(GlobeNewswire) +11.76%
May-15-23 04:05PM
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -7.34%
May-08-23 08:00AM
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
(GlobeNewswire)
Apr-24-23 09:55AM
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
(Zacks)
Apr-04-23 12:00PM
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
(Zacks) -5.01%
Mar-30-23 04:05PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Mar-16-23 08:00AM
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
(GlobeNewswire)
Mar-07-23 08:00AM
Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference
(GlobeNewswire) -5.26%
04:05PM Loading…
Mar-01-23 04:05PM
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
(GlobeNewswire)
Feb-27-23 04:05PM
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
(GlobeNewswire)
Feb-22-23 08:41PM
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
(GlobeNewswire)
04:05PM
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
(GlobeNewswire)
Feb-15-23 08:00AM
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
(GlobeNewswire)
Feb-13-23 07:00AM
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
(GlobeNewswire)
Jan-30-23 08:00AM
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
(GlobeNewswire)
Jan-19-23 08:00AM
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
(GlobeNewswire) -7.57%
Jan-12-23 09:56AM
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
(Zacks)
Jan-11-23 08:00AM
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
(GlobeNewswire) +11.99%
Nov-09-22 04:15PM
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Sep-22-22 06:00PM
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
(GlobeNewswire)
Sep-08-22 08:00AM
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
(GlobeNewswire)
Aug-11-22 04:15PM
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Aug-02-22 08:00AM
Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
(GlobeNewswire)
May-19-22 06:30AM
The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal
(American City Business Journals)
May-16-22 09:21AM
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
(GlobeNewswire) -19.09%
Mar-15-22 04:15PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire) +5.45%
Mar-02-22 04:41AM
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?
(Simply Wall St.)
Jan-14-22 10:00AM
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-06-22 08:00AM
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
(GlobeNewswire)
Dec-14-21 08:00AM
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire) -10.05%
Dec-13-21 08:00AM
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire) -10.85%
Dec-10-21 10:30AM
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
(Zacks)
Dec-09-21 12:30PM
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies
(Benzinga)
08:00AM
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
(GlobeNewswire)
Nov-08-21 04:15PM
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Nov-04-21 04:15PM
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
(GlobeNewswire)
Sep-21-21 08:39AM
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
(Benzinga)
07:01AM
18 Stocks Moving in Tuesday's Pre-Market Session
(Benzinga)
Sep-20-21 04:15PM
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
(GlobeNewswire)
08:42AM
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?
(Zacks)
Sep-14-21 08:00AM
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
(GlobeNewswire)
Sep-03-21 07:21AM
Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares?
(Simply Wall St.)
Aug-12-21 04:15PM
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
06:00AM
Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
(GlobeNewswire)
Aug-05-21 05:00PM
Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
(GlobeNewswire)
Jul-21-21 08:00AM
Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
(GlobeNewswire) -5.52%
Jun-18-21 08:34AM
Implied Volatility Surging for Aprea (APRE) Stock Options
(Zacks)
Jun-17-21 09:19AM
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
(Zacks) -6.32%
Jun-16-21 09:24AM
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
(Benzinga) +10.93%
08:00AM
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
(GlobeNewswire)
Jun-13-21 12:45PM
Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy?
(Insider Monkey)
Jun-04-21 01:47AM
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth?
(Simply Wall St.)
May-21-21 06:00AM
Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
(GlobeNewswire)
May-18-21 06:00AM
Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
May-06-21 04:15PM
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Apr-16-21 09:15AM
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
(GlobeNewswire) +7.64%
Apr-08-21 11:15AM
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
(GlobeNewswire) +13.64%
Mar-16-21 04:15PM
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
(GlobeNewswire)
Feb-16-21 08:04AM
Is Aprea Therapeutics, Inc. (NASDAQ:APRE) Popular Amongst Institutions?
(Simply Wall St.)
Jan-22-21 12:00PM
What Makes Aprea Therapeutics, Inc. (APRE) a New Buy Stock
(Zacks)
Jan-08-21 08:00AM
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
(GlobeNewswire)
Dec-30-20 11:40AM
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
(Zacks)
Dec-29-20 07:24PM
Dont Go Bargain Hunting on Aprea Stock, Says Analyst
(TipRanks) -8.18%
10:32AM
Aprea (APRE) Plunges as Late-Stage MDS Study Fails to Meet Goal
(Zacks)
Dec-28-20 04:57PM
10 Biggest Stock Gainers and Losers Today
(Insider Monkey) -78.08%
02:22PM
Aprea Shares Slump After Cancer-Drug Trial Misses Key Goal
(TheStreet.com)
08:00AM
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
(GlobeNewswire)
Dec-10-20 10:33PM
Is APRE A Good Stock To Buy Now?
(Insider Monkey)
Nov-30-20 08:00AM
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
(GlobeNewswire)
Nov-23-20 10:00AM
3 Stocks with Jaw-Dropping Growth Potential
(Motley Fool)
Nov-19-20 08:00AM
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-05-20 04:15PM
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
(GlobeNewswire) -8.52%
Oct-30-20 04:00AM
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
(GlobeNewswire)
Oct-14-20 08:00AM
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
(GlobeNewswire)
Oct-07-20 08:00AM
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
(GlobeNewswire) +8.85%
Sep-29-20 08:00AM
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
(GlobeNewswire)
06:28AM
Should You Take Comfort From Insider Transactions At Aprea Therapeutics, Inc. (NASDAQ:APRE)?
(Simply Wall St.)
Sep-18-20 08:00AM
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
(GlobeNewswire)
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seizinger Bernd R.DirectorMar 13 '24Buy7.296,86050,00933,685Mar 14 08:53 PM
HENNEMAN JOHN B IIIDirectorMar 13 '24Buy7.296,86050,0098,139Mar 14 08:52 PM
Gilad OrenPresident, CEOMar 13 '24Buy7.292,00014,580324,770Mar 14 08:51 PM
Hamill John P.SrVP/CFO/Prin Fin & Acct OfcrMar 13 '24Buy7.291,0107,36315,503Mar 14 08:54 PM
Seizinger Bernd R.DirectorJun 07 '23Buy3.686,02922,19226,325Jun 08 04:34 PM
Seizinger Bernd R.DirectorJun 06 '23Buy3.634,06814,76420,296Jun 08 04:34 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

APTO

Aptose Biosciences Inc

Last Close
May 15 • 04:00PM ET
1.18
Dollar change
-0.05
Percentage change
-4.06 		%
APTO Aptose Biosciences Inc daily Stock Chart
Index- P/E- EPS (ttm)-6.27 Insider Own40.54% Shs Outstand16.25M Perf Week-4.06%
Market Cap19.18M Forward P/E- EPS next Y-2.54 Insider Trans0.00% Shs Float9.66M Perf Month-7.08%
Income-47.17M PEG- EPS next Q-0.78 Inst Own7.45% Short Float0.86% Perf Quarter-39.48%
Sales0.00M P/S- EPS this Y58.41% Inst Trans4.58% Short Ratio1.16 Perf Half Y-56.93%
Book/sh0.01 P/B135.33 EPS next Y19.48% ROA-180.99% Short Interest0.08M Perf Year-83.33%
Cash/sh0.57 P/C2.06 EPS next 5Y- ROE-361.05% 52W Range1.15 - 7.74 Perf YTD-53.54%
Dividend Est.- P/FCF- EPS past 5Y10.18% ROI-7179.76% 52W High-84.75% Beta1.42
Dividend TTM- Quick Ratio0.97 Sales past 5Y0.00% Gross Margin- 52W Low2.62% ATR (14)0.07
Dividend Ex-Date- Current Ratio0.97 EPS Y/Y TTM12.30% Oper. Margin0.00% RSI (14)37.60 Volatility4.86% 4.87%
Employees35 Debt/Eq6.57 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.80
Option/ShortNo / Yes LT Debt/Eq3.71 EPS Q/Q66.88% Payout- Rel Volume0.59 Prev Close1.23
Sales Surprise- EPS Surprise33.47% Sales Q/Q- EarningsMay 14 AMC Avg Volume72.07K Price1.18
SMA20-3.23% SMA50-15.08% SMA200-51.35% Trades Volume42,831 Change-4.06%
Date Action Analyst Rating Change Price Target Change
Oct-19-20Initiated Cantor Fitzgerald Overweight $10
Sep-22-20Initiated Alliance Global Partners Buy $12
Feb-20-20Initiated Maxim Group Buy $16
Feb-06-20Reiterated H.C. Wainwright Buy $6 → $9
Jan-09-20Initiated Piper Sandler Overweight $10
Mar-01-19Initiated RBC Capital Mkts Outperform $6
Nov-16-18Initiated B. Riley FBR Buy $5
Dec-13-17Reiterated H.C. Wainwright Buy
Oct-23-17Resumed ROTH Capital Buy $5
Sep-07-17Upgrade H.C. Wainwright Neutral → Buy $1 → $4
Show Previous Ratings
May-14-24 09:54PM
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024
(InvestorPlace)
04:32PM
Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses
(MT Newswires)
04:21PM
Aptose Biosciences: Q1 Earnings Snapshot
(Associated Press Finance)
04:01PM
Aptose Reports Results for the First Quarter 2024
(GlobeNewswire)
May-06-24 04:30PM
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
(GlobeNewswire)
12:00PM Loading…
Apr-05-24 12:00PM
What Makes Aptose Biosciences (APTO) a New Buy Stock
(Zacks)
Mar-27-24 08:26AM
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
(Insider Monkey) -6.25%
Mar-26-24 08:53PM
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
(InvestorPlace) +5.96%
04:01PM
Aptose Reports Results for the Fourth Quarter and Full Year 2023
(GlobeNewswire)
Mar-18-24 04:30PM
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
(GlobeNewswire)
Jan-31-24 04:01PM
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
(GlobeNewswire)
Jan-26-24 08:36AM
Why Is Aptose Biosciences (APTO) Stock Down Today?
(InvestorPlace)
08:00AM
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
(GlobeNewswire)
Dec-09-23 06:30PM
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
(GlobeNewswire)
Nov-30-23 04:59PM
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
(GlobeNewswire) -9.29%
11:21AM Loading…
Nov-10-23 11:21AM
Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript
(Insider Monkey) -24.38%
Nov-09-23 04:17PM
Aptose Biosciences: Q3 Earnings Snapshot
(Associated Press Finance) +5.88%
04:00PM
Aptose Reports Results for the Third Quarter 2023
(GlobeNewswire)
Nov-02-23 09:00AM
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
(GlobeNewswire)
Oct-30-23 09:15AM
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
(GlobeNewswire) -13.52%
Oct-26-23 07:11AM
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
(GlobeNewswire) +9.30%
Oct-23-23 07:30AM
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
(GlobeNewswire)
Oct-16-23 07:30AM
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
(GlobeNewswire) +30.84%
Sep-18-23 07:45AM
Aptose to Present at the Cantor Global Healthcare Conference
(GlobeNewswire) +5.17%
Sep-06-23 07:45AM
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
(GlobeNewswire) -6.19%
Aug-24-23 07:30AM
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-10-23 04:08PM
Aptose Biosciences: Q2 Earnings Snapshot
(Associated Press Finance) +6.38%
04:02PM
Aptose Reports Results for the Second Quarter 2023
(GlobeNewswire)
Jul-27-23 04:04PM
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
(GlobeNewswire)
Jun-26-23 04:05PM
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
(GlobeNewswire)
12:00PM Loading…
Jun-10-23 12:00PM
Aptose Presents Highlights from Clinical Update
(GlobeNewswire)
Jun-05-23 07:30AM
Aptose Biosciences Provides Update on Reverse Stock Split
(GlobeNewswire)
May-31-23 07:30AM
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
(GlobeNewswire)
May-25-23 04:14PM
Aptose Enters into $25 Million Committed Equity Facility
(GlobeNewswire) -6.37%
May-23-23 05:30PM
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
(GlobeNewswire)
May-21-23 10:03AM
3 Stocks With 1,000% Upside Potential
(InvestorPlace)
May-11-23 07:28AM
Aptose Biosciences Inc.'s (TSE:APS) Path To Profitability
(Simply Wall St.)
May-08-23 04:13PM
Aptose Biosciences: Q1 Earnings Snapshot
(AP Finance)
04:01PM
Aptose Reports Results for the First Quarter 2023
(GlobeNewswire)
May-04-23 07:01AM
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
(GlobeNewswire)
Apr-24-23 07:01AM
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
(GlobeNewswire)
Apr-10-23 04:01PM
Aptose to Participate in Canaccord Genuitys 2023 Horizons in Oncology Virtual Conference
(GlobeNewswire)
Mar-28-23 04:01PM
Aptose Biosciences to Participate in Cantors The Future of Oncology Virtual Symposium
(GlobeNewswire)
09:40AM
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
(Zacks)
Mar-27-23 08:45AM
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-23-23 04:44PM
Aptose Reports Results for the Fourth Quarter and Full Year 2022
(GlobeNewswire)
Mar-10-23 06:44PM
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
(GlobeNewswire) -5.33%
Mar-09-23 04:05PM
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
(GlobeNewswire)
Mar-02-23 07:30AM
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
(GlobeNewswire)
Jan-30-23 07:00AM
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
(GlobeNewswire)
Dec-30-22 08:02AM
We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully
(Simply Wall St.) +7.61%
Dec-28-22 07:30AM
Aptose Biosciences to Present at Biotech Showcase 2023 Conference
(GlobeNewswire) +7.77%
Dec-12-22 06:15AM
Aptose Biosciences Establishes New At-The-Market Facility
(GlobeNewswire)
Dec-11-22 09:00AM
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
(GlobeNewswire)
Dec-07-22 04:05PM
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
(GlobeNewswire)
Nov-14-22 07:30AM
Aptose Treats First Patient with Continuous Dosing of New G3 Formulation of Luxeptinib
(GlobeNewswire)
Nov-03-22 09:10AM
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
(GlobeNewswire) +30.55%
Nov-01-22 04:01PM
Aptose Reports Results for the Third Quarter 2022
(GlobeNewswire) +8.32%
Oct-18-22 04:01PM
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
(GlobeNewswire) -6.03%
Sep-30-22 08:59AM
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
(Zacks)
Sep-29-22 11:09AM
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
(Zacks)
Sep-28-22 01:47PM
Merck's (MRK) Keytruda Gets Four New Approvals in Japan
(Zacks) +6.45%
Sep-27-22 11:44AM
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
(Zacks)
10:13AM
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
(Zacks)
Sep-21-22 06:32PM
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
(Zacks)
Sep-20-22 09:49AM
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication
(Zacks)
Sep-19-22 12:28PM
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
(Zacks)
Sep-14-22 07:30AM
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
(GlobeNewswire)
Sep-13-22 03:45PM
Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal
(Zacks)
08:44AM
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
(Zacks)
07:30AM
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
(GlobeNewswire)
Sep-12-22 07:30AM
Aptoses New G3 Formulation of Luxeptinib Boosts Bioavailability
(GlobeNewswire)
Aug-30-22 07:30AM
Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference
(GlobeNewswire)
Aug-02-22 04:01PM
Aptose Reports Results for the Second Quarter 2022
(GlobeNewswire)
Jul-27-22 07:30AM
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
(GlobeNewswire)
Jul-23-22 08:08AM
Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth?
(Simply Wall St.)
Jul-19-22 04:01PM
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
(GlobeNewswire)
Jun-27-22 07:30AM
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer
(GlobeNewswire)
Jun-02-22 08:10PM
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
(GlobeNewswire)
05:30PM
Aptose Presents Highlights from Corporate Update and KOL Event
(GlobeNewswire)
May-31-22 04:15PM
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
(GlobeNewswire) +5.96%
May-25-22 08:30AM
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
(GlobeNewswire)
May-12-22 10:00AM
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd
(GlobeNewswire) +6.22%
May-09-22 04:01PM
Aptose Reports Results for the First Quarter 2022
(GlobeNewswire)
May-04-22 07:30AM
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
(GlobeNewswire)
May-03-22 07:30AM
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
May-02-22 04:10PM
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
(GlobeNewswire)
Apr-25-22 07:30AM
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
(GlobeNewswire)
Apr-07-22 07:00AM
Aptose Announces Executive Management Changes
(GlobeNewswire)
Mar-31-22 07:30AM
Aptose to Present at Canaccord Genuitys 2022 Horizons in Oncology Virtual Conference
(GlobeNewswire) +7.94%
Mar-22-22 04:01PM
Aptose Reports Results for the Fourth Quarter and Full Year 2021
(GlobeNewswire)
Mar-08-22 07:30AM
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
(GlobeNewswire)
Mar-01-22 07:30AM
Aptose to Present at Oppenheimers 32nd Annual Healthcare Conference
(GlobeNewswire)
Feb-13-22 06:39AM
We Think Aptose Biosciences (TSE:APS) Can Afford To Drive Business Growth
(Simply Wall St.)
Dec-31-21 01:50PM
5 Beaten-Down Biotech Bets to Bounce Back in 2022
(Zacks)
Dec-29-21 07:30AM
Aptose to Participate in Two Biotech Events in January 2022
(GlobeNewswire)
Dec-28-21 09:38AM
Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...
(GuruFocus.com)
Dec-21-21 09:38AM
Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...
(GuruFocus.com) +7.91%
Dec-20-21 07:30AM
Aptose Provides Update on APTO-253 Program
(GlobeNewswire) -7.33%
Dec-16-21 09:14AM
10 Micro-Cap Stocks to Buy According to Hedge Funds
(Insider Monkey) +23.53%
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seizinger Bernd R.DirectorSep 22 '23Buy3.1417,00053,38017,000Sep 25 05:03 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.